Welcome to our dedicated page for Immunocore Holdings Plc news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings Plc stock.
Immunocore Holdings plc (Nasdaq: IMCR) is a commercial-stage biotechnology company focused on T cell receptor (TCR) bispecific immunotherapies for cancer, infectious diseases and autoimmune diseases. News about Immunocore frequently centers on the commercial performance and clinical development of its lead product, KIMMTRAK, which is approved for HLA‑A*02:01‑positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, and on its broader melanoma franchise.
Investors following IMCR news can expect regular updates on Phase 3 oncology trials, including the TEBE‑AM registrational trial of tebentafusp in second‑line or later advanced cutaneous melanoma, the ATOM adjuvant uveal melanoma trial, and the PRISM‑MEL‑301 trial evaluating brenetafusp plus nivolumab in first‑line advanced cutaneous melanoma. Company press releases also describe progress in Phase 1/2 studies of PRAME‑targeting ImmTAC candidates across ovarian cancer, non‑small cell lung cancer and other solid tumors.
Beyond oncology, Immunocore issues news on its ImmTAV infectious disease programs, such as IMC‑M113V for people living with HIV and IMC‑I109V for chronic hepatitis B infection, including early clinical data on safety, pharmacodynamic effects and viral antigen reductions. Updates on ImmTAAI candidates for autoimmune conditions, including type 1 diabetes and inflammatory dermatological diseases, are also part of the company’s communications.
This IMCR news page aggregates company press releases, conference participation announcements and SEC‑related disclosures, giving readers a single view of developments in KIMMTRAK commercialization, pipeline milestones, trial readouts and strategic priorities across oncology, infectious disease and autoimmune pipelines.
Immunocore Holdings plc (Nasdaq: IMCR) announced that its Chief Financial Officer (CFO) and Head of Strategy, Brian Di Donato, will be leaving the company at the end of 2024. Di Donato has accepted a position as CEO of a private, early-stage biotech in San Diego. He will remain in his current role through the end of the year to ensure a smooth transition, while Immunocore initiates a search for a new CFO.
CEO Bahija Jallal praised Di Donato's contributions over his four-year tenure, highlighting his role in the company's successful IPO and building a strong Finance department. Di Donato expressed pride in Immunocore's achievements, including becoming a commercial-stage biotech with the launch of the world's first TCR therapy.
Immunocore Holdings plc (Nasdaq: IMCR) reported Q2 2024 financial results and provided a business update. Key highlights include:
- KIMMTRAK net revenues of $75.3 million in Q2 2024, driven by US growth
- Ongoing Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma
- Started randomization for Phase 3 PRISM-MEL-301 trial evaluating brenetafusp + nivolumab in first-line cutaneous melanoma
- Presented Phase 1 data of brenetafusp in late-line cutaneous melanoma at ASCO 2024
- R&D expenses increased to $51.1 million in Q2 2024
- Cash, cash equivalents, and marketable securities at $859.6 million as of June 30, 2024
The company is advancing multiple clinical programs and expects data readouts over the next 18 months.
Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company, has announced it will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the US markets open. The company will host a live teleconference and webcast at 8:00 a.m. EDT (1:00 p.m. BST) to discuss the financial results and provide a business and portfolio update.
Investors and interested parties can access the audio webcast through the 'Events' section under 'Events and Presentations' on Immunocore's website. For those who prefer to join via phone, domestic toll-free and international toll numbers have been provided. A replay of the event will be available for a time after the call.
Immunocore announced the randomization of the first patient in its global Phase 3 PRISM-MEL-301 trial. This trial assesses the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02) combined with nivolumab, compared to nivolumab or nivolumab + relatlimab in treating first-line advanced or metastatic cutaneous melanoma. The trial targets HLA-A*02:01 positive patients. Brenetafusp is a PRAME x CD3 ImmTAC bispecific protein. Previous Phase 1 data showed it was well tolerated and demonstrated promising monotherapy activity.
Immunocore presented new clinical data for KIMMTRAK at the 2024 ASCO Annual Meeting. The data showed that patients with unresectable or metastatic uveal melanoma who had stable disease and confirmed tumor reduction experienced similar clinical outcomes to those with a partial response. The Phase 2 trial indicated that 25% of 127 patients had any tumor reduction, including 6 partial responses. In the Phase 3 trial, the durability of tumor reduction was similar for patients with stable disease and partial response, both lasting 11 months. This reinforces KIMMTRAK as a standard treatment for HLA-A*02:01-positive patients.
Immunocore has released updated Phase 1 data for brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients. The study showed promising disease control rates, progression-free survival (PFS), and molecular responses, particularly in PRAME positive patients. Brenetafusp was well tolerated as a monotherapy and in combination with anti-PD1. The Phase 3 clinical trial (PRISM-MEL-301) is now enrolling patients for first-line advanced cutaneous melanoma treatment. Detailed results will be presented at the ASCO 2024 meeting.
Immunocore, a Nasdaq-listed commercial-stage biotech firm specializing in immunomodulating medicines for cancer, infectious and autoimmune diseases, announced its participation in the Jefferies Global Healthcare Conference.
The event is scheduled for June 6, 2024, at 2:30 p.m. EDT.
A live webcast of the presentation will be available on the Immunocore website, with a replay accessible post-event.
Immunocore has announced the conversion of its Phase 2/3 TEBE-AM trial into a registrational Phase 3 trial to evaluate KIMMTRAK (tebentafusp-tebn) for previously treated advanced cutaneous melanoma. Following FDA consultation, all patients from the Phase 2/3 trial will be included in the Phase 3 intent-to-treat population. The Phase 3 trial will continue with three arms: KIMMTRAK monotherapy, KIMMTRAK with pembrolizumab, and a control.
This decision is expected to accelerate the time to the final overall survival analysis. The conversion was motivated by KIMMTRAK’s promising results in uveal melanoma and Phase 1 cutaneous melanoma trials. The Phase 1b study showed that KIMMTRAK, combined with checkpoint inhibitors, had a one-year overall survival rate of approximately 75% in patients with metastatic cutaneous melanoma.
Immunocore reported first quarter financial results with KIMMTRAK® net revenues of $70.3 million in Q1 2024. The company continues to expand global access with 7 additional launches since January 2024. Phase 1/2 brenetafusp clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024. Financially, the company saw a 36% increase in net product revenue, with total revenue reaching $70.3 million in Q1 2024. However, research & development expenses also grew, resulting in a net loss for the quarter. Cash and cash equivalents stood at $832.8 million as of March 31, 2024.
Summary not available.